ClinicalTrials.gg
CompletedNCT04637529APS003/2020Updated Sep 8, 2026

Efficacy and Safety of S (+) - Ibuprofen in Osteoarthritis Pain

A Phase 2 interventional study of S (+) - Ibuprofen and Ibuvix® - ibuprofen in Osteoarthritis, sponsored by Apsen Farmaceutica S.A.. Completed at 1 site in Brazil. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-08.

Sponsored by Apsen Farmaceutica S.A. · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
176
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 57 studies in Osteoarthritis with a site in Brazil — 3 open to participants now, 3 under way, 2 of them phase 3. Osteoarthritis · Brazil.

Enrollment
9th of 56
176 · median 71
Started
2022
the only one that year
Phase 2
6 of 57
none open now
Registered
50th of 57
by date
Lead sponsor
1 of 57
Apsen Farmaceutica S.A.

Among the 57 studies in Osteoarthritis with a site in Brazil, this one is the 9th largest by enrollment of the 56 interventional ones that give a count, is the only one that started in 2022, is one of 6 in phase 2, and was the 50th registered.

Osteoarthritis

2,977 studies on the registry are indexed under Osteoarthritis; 438 are open to participants now.

Browse Osteoarthritis studies →

Open to participants now

3 of the 57 studies in Osteoarthritis with a site in Brazil are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 285 Osteoarthritis studies recruiting now, 158 (55%) set no upper age limit and 70 (25%) stop at 75 or younger; 22 take children under 18; 31 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies in Osteoarthritis with a site in Brazil, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy of S (+) - ibuprofen compared to an active treatment for pain control in individuals diagnosed with osteoarthritis.

03

Conditions studied

  • Osteoarthritis

Keywords

  • Nonsteroidal anti-inflammatory
  • Pain
  • Ibuprofen
  • Inflammation
  • Anti-inflammatory
  • Pain control
  • Osteoarthritis
  • Pain relief
  • Enzyme Inhibitors
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  • Ability to confirm voluntary participation and agree to all trial purposes by signing and dating the forms;
  • Patients aged from 18 to 75 with a diagnosis of knee and/or hip osteoarthritis according to American College of Rheumatology (ACR) criteria.

Main Exclusion Criteria:

  • Known to the formula components used during the clinical trial;
  • Previous history of alcohol or drugs abuse diagnosed by ;
  • Current or previous history (less than 12 months) of smoking;
  • Have abnormal laboratory results according to medical evaluation;
  • Women who are pregnant, lactating, or positive for β - hCG urine test;
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
176 participants (actual)

Study arms

  • Experimental
    S (+) - Ibuprofen

    S (+) - Ibuprofen (1 coated tablet) + placebo of Ibuvix® - ibuprofen (1 coated tablet) Every 6 hours for 28 days.

    Drug: S (+) - Ibuprofen

  • Active comparator
    Ibuvix® - ibuprofen

    Ibuvix® - ibuprofen (1 coated tablet) + placebo of S (+) - Ibuprofen (1 coated tablet) Every 6 hours for 28 days.

    Drug: Ibuvix® - ibuprofen

Interventions

  • DrugS (+) - Ibuprofen

    S (+) - Ibuprofen + placebo of Ibuvix®

  • DrugIbuvix® - ibuprofen

    Ibuvix® + placebo of S(+) - Ibuprofen

06

What researchers measure

Primary outcomes

  1. Mean reduction of pain measured by the WOMAC Osteoarthritis Index (pain)

    Time frame: Baseline (day 0) and Week 4 (day 28)

Secondary outcomes

  1. Patient Global Impression of Improvement-I (PGI-I)

    Time frame: Week 4 (day 28)

  2. Proportion of participants among the groups to discontinue the trial due to treatment non-tolerability

    Time frame: From Baseline (day 0) to Week 4 (day 28)

07

Study locations

1 site
  • Apsen Farmacêutica S.A.
    São Paulo, São Paulo 04753-001, Brazil
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2022 to primary completion in Jun 2023, 10 months.

Of 54 industry-sponsored phase 2 interventional studies under Osteoarthritis, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 32. This study's 10 months is below that.

Counting every sponsor, half of 82 studies reached it within 19 months; a quarter within 10 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2020
First posted
Nov 19, 2020
StartActual
Aug 5, 2022
Primary completionActual
Jun 30, 2023
CompletionActual
Jun 30, 2023
Last update
Sep 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04637529
Lead sponsor
Apsen Farmaceutica S.A.
Responsible party
Sponsor
First posted
Nov 19, 2020
Start date
Aug 5, 2022
Primary completion
Jun 30, 2023
Completion
Jun 30, 2023
Last update
Sep 8, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion